Abstract
Voltage-gated sodium channel blockers have long been used in the therapy of various central nervous system diseases, including epilepsy, chronic pain, psychiatric disorders, and spasticity. Several old agents are available with suboptimal features. Their properties may be improved by enhancing their state-dependent channel blocking action, and/or sodium channel subtype selectivity. This paper gives a short overview on the present state of research in this field, and the chemical structures of old sodium channel blockers, and those of recently published or patented compounds with sodium channel blocking action.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
